Juliette Han, Chief Financial Officer and Chief Operating Officer at Cambrian BioPharma discusses the company’s work in discovering treatments that increase healthspan and why people living longer would benefit the economy/society. She talks about the importance of the healthcare industry sharing clinical and experimental data transparently with one another to collectively solve healthcare issues and investing in preventative medicines rather than focusing just on treatments.
Juliette Han is the Chief Financial Officer & Chief Operating Officer at Cambrian BioPharma. She is also an adjunct professor at Columbia Business School and an academic advisor at Harvard Medical School. Han was previously the Chief of Staff at Two Sigma Private Investments Group, the Private Investments division of the hedge fund Two Sigma. Prior to Two Sigma, Han was a Chief Operating Officer of People – Human Resources Operations at the hedge fund Citadel, where she led strategic thinking behind performance and teams. Prior to Citadel, Han was Chief of Staff for McKinsey New Ventures at McKinsey & Company and a strategy and commercialization consultant in the New York office’s pharmaceutical practice. Han holds a Ph.D. in Neuroscience from Harvard University, as well as an M.S. in Physiological Sciences and B.S. in Neuroscience and Physiological Science, both from UCLA. She serves on the alumni advisory council of Harvard Medical School, Division of Medical Sciences.